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Mitochondria play an important role in many processes, like glucose metabolism, fatty acid oxidation and
ATP synthesis. In this study, we aimed to identify association of common polymorphisms in nuclear-encoded
genes involved in mitochondrial protein synthesis and biogenesis with type II diabetes mellitus (T2DM) using
a two-stage design. In the first stage, we analyzed 62 tagging single nucleotide polymorphisms (SNPs) in the
Hoorn study (n¼ 999 participants) covering all common variation in 13 biological candidate genes. These 13
candidate genes were selected from four clusters regarded essential for correct mitochondrial protein
synthesis and biogenesis: aminoacyl tRNA synthetases, translation initiation factors, tRNA modifying
enzymes and mitochondrial DNA transcription and replication. SNPs showing evidence for association with
T2DM were measured in second stage genotyping (n¼10164 participants). After a meta-analysis, only one
SNP in SIRT4 (rs2522138) remained significant (P¼0.01). Extending the second stage with samples from the
Danish Steno Study (n¼1220 participants) resulted in a common odds ratio (OR) of 0.92 (0.85–1.00),
P¼0.06. Moreover, in a large meta-analysis of three genome-wide association studies, this SNP was also not
associated with T2DM (P¼0.72). In conclusion, we did not find evidence for association of common variants
in 13 nuclear-encoded mitochondrial proteins with T2DM.
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Introduction
Mutations in genes involved in mitochondrial protein
synthesis have been found to associate with a diabetic
state. The 3243A4G mutation in the mitochondrial tRNA
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(Leu, UUR) gene, which impairs mitochondrial protein
synthesis, is strongly diabetogenic, as are some additional
mutations in mtDNA-encoded tRNA genes.1,2 Recently, we
found that an H324Q variant in the nuclear-encoded
mitochondrial leucyl tRNA synthetase (LARS2) results in an
increased type II diabetes mellitus (T2DM) susceptibility.3
It seems that a change in the activity of mitochondrial
protein synthesis makes the organism more vulnerable to
develop glucose intolerance.
A change in mitochondrial protein synthesis is
expected to result in an unbalance in the stoichiometry
of the proteins composing the respiratory chain. Some
proteins of the respiratory chain are synthesized through
the mitochondrial protein synthesis machinery, whereas
the others are synthesized in the cytosol and imported into
the mitochondrion. Therefore, impaired activity of the
mitochondrial protein synthesis machinery is expected to
result in an unbalance between the nuclear DNA- and
mitochondrial DNA-encoded proteins of the respiratory
chain. A similar situation of an unbalance may arise when
the rate of mitochondrial biogenesis is altered.
In T2DM, a reduced activity of the respiratory chain is
seen, which is also present in the first degree relatives.4,5
The biochemical basis of this phenomenon may arise
through an unbalanced expression of the various proteins.
On the basis of these considerations, we hypothesized that
polymorphisms in genes involved in mitochondrial pro-
tein synthesis and mitochondrial biogenesis may alter the
balanced expression of proteins of the respiratory chain. As
a result, these polymorphisms are expected to modify the
risk for T2DM. It is estimated that the complete mitochon-
drial proteome consists of approximately 1500 proteins,
which are mostly encoded by the nuclear genome.6
Common variations in genes encoded by the mitochon-
drial genome are not associated with the onset of T2DM.7,8
Based on a literature study, we selected 13 candidate genes
divided in several clusters. These candidates are all nuclear
genes encoding for mitochondrial proteins.
Owing to the previous association of LARS2 with T2DM,
the first cluster consisted of the mitochondrial aminoacyl-
tRNA synthetases DARS2, TARS2 and IARS2. DARS2 and
TARS2 are located on a widely replicated T2DM linkage
locus on chromosome 1q.9 Furthermore, variants in the
tRNAIle gene were shown to be associated with metabolic
disorders.10
The second cluster consisted of the two mitochondrial
translation initiation factors, MTIF2 and MTIF3. These two
genes are involved in initiation of the mitochondrial
protein synthesis and their dysfunction could lead to
altered expression of mitochondrial proteins, and subse-
quently to oxidative stress and late-onset disease.11–13 We
have selected them above other important translation
factors, like TUFM, TSFM and GFM1, because mutations
in the latter have already been associated with severe
early-onset disease.14
The third cluster consisted of MTO1, TRMU and GTPBP3,
which encode tRNA modifying enzymes. Variation in
these genes could lead to dysfunctional enzymes and
subsequently result in impaired tRNA modification and
mitochondrial disease.15–17
In our fourth cluster, we included TFAM and PPRC1,
which are involved in transcription and replication of the
mitochondrial genome. It has been shown earlier that a
low mitochondrial copy number is associated with T2DM,
although this is not confirmed in all studies.18,19 TFAM is
one of the main regulators of mitochondrial transcription
and replication, and thus of the mitochondrial copy
number.20,21 PPRC1 is a PPARGC1A-related gene and
involved in mitochondrial biogenesis.22
In addition, we selected three genes, which did not fit in
a specific cluster but may affect mitochondrial biogenesis
and function. SIRT3 and SIRT4, which are Sir2 homologs,
are involved in mitochondrial function and insulin
secretion.23,24 Moreover, SIRT3 has been associated with
longevity.25 GPAM is the final candidate gene, which is
involved in triacylglycerol and phospholipid synthesis.
GPAM knockout mice show hyperinsulinaemia and redu-
ced glucose tolerance.26,27 Therefore, we hypothesized
that defects in GPAM could lead to insulin resistance and
subsequently to T2DM.
Dysfunction of these 13 candidate genes potentially
affects mitochondrial function and may therefore increase
T2DM susceptibility. Therefore, the aim of this study was
to analyze the association of common variants in these
gene loci with T2DM, using a tagging single nucleotide
polymorphism (SNP) approach.
Materials and methods
Single nucleotide polymorphism selection
Tagging SNPs were selected using the HapMap database
(www. HAPMAP.org) and Tagger.28,29 The threshold for the
minor allele frequency (MAF) was set at 0.05. Using Tagger,
62 SNPs were selected, which cover all common variation
in the selected genes according to HapMap data (phase 2,
April 2007 (Build 36), population CEU, r240.8). Aggressive
tagging with two- and three-marker tests was used. This
resulted in four multimarker tests. The remaining tests
were all single marker tests. Gene boundaries include
50 and 30-UTR regions. Details about the SNP selection for
the individual genes, including gene boundaries, are
summarized in Table 1.
Genotyping and quality control
A two-stage design was used. For first-stage genotyping, the
Sequenom platform (Sequenom, San Diego, CA, USA) was
used. First, the allelic discrimination plots were visually
observed for good clustering. Assays with bad clustering
were not further analyzed. SNPs with a success rate below
95% or not obeying Hardy–Weinberg Equilibrium
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(Po0.01) were excluded from analysis. SNPs, which did not
fit in the Sequenom assay or failed quality control (QC),
were genotyped with Taqman SNP genotyping assays
(Applied Biosystems, Foster City, CA, USA) and evaluated
with the same QC guidelines. Duplicate samples (B5%)
showed identical genotypes. SNPs showing evidence for
association with T2DM (Po0.05) were selected for second-
stage genotyping. Taqman SNP genotyping assays were
used for this.
Study cohorts
The first-stage genotyping was performed in the Hoorn
study.30 This population-based study consisted of 519
normal glucose tolerant (NGT) participants (aged 65±8
years, 55% male) and 480 T2DM participants (aged 67±8
years, 52% male). Glucose tolerance was tested using a
fasting oral glucose tolerance test (OGTT), according to
World Health Organization (WHO) criteria.31
For the second-stage genotyping, three cohorts from
the Netherlands were pooled. The first cohort was the
New Hoorn Study (NHS), which is an ongoing, second
non-overlapping population-based study in Hoorn.32
From this study, we randomly selected 1517 NGT and 147
T2DM participants. All participants underwent an OGTT
according to WHO criteria.31 To increase power, we
included 674 participants with T2DM from the diabetes
clinics of the Leiden University Medical Center (LUMC,
Leiden, The Netherlands) and from the Vrije Universiteit
medical center (VUmc, Amsterdam, The Netherlands). All
participants were Dutch caucasians. In total, the NHS
sample included 1517 controls (aged 53±7 years, 44%
male) and 821 cases (aged 61±11 years, 50% male).
The second cohort was the Breda study.33,34 This case–
control study consisted of 920 healthy controls (according
to self report) from the Dutch blood bank (aged 48±13
years, 61% male). 501 cases (aged 71±10 years, 46% male)
were T2DM patients according to WHO criteria.31
The third cohort was the ERGO study from Rotterdam.35
This population-based study consisted of 5183 NGT
participants (aged 69±9 years, 41% male) and 1222
(73±9 years, 39% male) T2DM patients.
In total, for the second-stage genotyping, we used 7620
controls and 2544 T2DM cases. The characteristics of both
stages are summarized in Table 2 (Characteristics of the
independent cohorts are summarized in Supplementary
Table S1.). For additional replication of our strongest
signal, we extended the second stage with samples
from the Danish Steno study.36 This case–control study
Table 1 Gene boundaries and number of SNPs in the selected candidate genes
Gene Chromosome
Gene boundaries
for SNP selection
Number of SNPs
(successful)
% covered
(MAF40.05)
TARS2 1 148726544148746371 4 (4) 100
DARS2 1 172060581172094305 2 (1) 28
IARS2 1 218334078218387999 6 (4) 81
MTIF2 2 5531726255349888 7 (7) 100
MTO1 6 7422820974267896 5 (5) 100
TFAM 10 5981518159825901 5 (5) 100
PPRC1 10 103882777103900078 3 (3) 100
GPAM 10 113899611113933507 6 (6) 100
SIRT3 11 205031226361 10 (10) 100
SIRT4 12 119224546119235427 3 (3) 100
MTIF3 13 2690778326922711 3 (3) 100
GTPBP3 19 1730937917314530 4 (4) 100
TRMU 22 4510996245131900 4 (3) 81
Gene boundaries and coverage according to HapMap data. Gene boundaries according to genome build 36.
The widest gene boundaries were used when more isoforms were known.
Table 2 Descriptive statistics of the first and second stage
First stage Second stage
Controls Cases Controls Cases
Participants (% male) 519 (55) 480 (52) 7620 (44) 2544 (45)
Age – years (SD) 65 (8) 67 (8) 63 (12) 68 (12)
BMI – kg/m2 (SD) 26 (5) 29 (5) 26 (4) 27 (5)
FPG – mmol/l (SD) 5.4 (0.4) 7.7 (2.2) 5.5 (0.5)a 8.3 (2.5)a
FPG, fasting plasma glucose.
First stage consists of participants from the Hoorn study. 30 Second stage is a pooled sample of participants originally from the NHS, Breda and ERGO
studies.33 – 35
aAvailable for 2438 controls and 334 cases.
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consisted of 514 NGT controls (aged 57±10, 46% male)
randomly selected from public registers at the Steno
Diabetes Center and the Research Center for Prevention
and Health. The 706 cases (aged 59±10 years, 48% male)
were recruited from the Steno Diabetes Center.
Statistical analysis
Differences in genotype distribution and allele frequency
were analyzed using a w2 test. An additive model was the
best fit for most of the SNPs. rs1049432 (TFAM) and
rs4917960 (PPRC1) might better fit a recessive model, and
were therefore also analyzed with this model. A common
allelic odds ratio (OR) covering both stages was calculated
in a meta-analysis using a Mantel–Haenszel test. Homo-
geneity of ORs between the different cohorts was tested
using a Tarone’s test. Results from OGTT (only NGT
participants) were analyzed with univariate analysis of
variance, using additive, dominant and recessive models,
and correction for age, BMI and gender, as possible
confounders. Power calculations were performed using
Quanto.37 Power to detect modest effects in the first stage
was limited (80% power to detect, OR 1.45, MAF¼ 0.1).
Therefore, we did not correct for multiple testing but rather
performed extensive replication of all signals from the first
stage with Po0.05. All statistics were calculated using SPSS
14.0 (SPSS Inc., Chicago, IL, USA).
Results
Of the 62 SNPs tested in the first-stage genotyping, 58 SNPs
passed QC guidelines. Of these SNPs, we selected the top
seven SNPs for second-stage genotyping (Po0.05). Data
from genome-wide association studies (GWAS), which
became available after completion of our study, resulted
in the inclusion of two additional SNPs, rs4397793 in
TFAM and rs2792751 in GPAM. Compared with our data,
both showed a similar effect in at least one of the publicly
available databases of GWAS.38,39 In total, nine SNPs were
selected for genotyping in the second stage (Table 3).
We analyzed the second-stage results for rs1049432 in
TFAM and rs4917960 in PPRC1 first with a recessive
model, because that was the best fit for the first-stage
data (Prec¼0.002 and Prec¼0.07, respectively). However,
second-stage results showed no support for this model;
therefore, the additive model was used for further analyses.
There was no evidence of heterogeneity of ORs between
the independent cohorts; therefore, we pooled all the
second-stage data. A meta-analysis of both stages was
performed to calculate a common OR for the nine selected
SNPs (Table 3). Only the G allele of rs2522138 in SIRT4
remained significant (P¼0.01), but this was mainly caused
by first-stage results. To confirm the observed association,
we expanded the second stage with the Danish Steno study
resulting in a common OR of 0.92 (0.85–1.00), P¼ 0.06.
The C allele of rs4917960 in PPRC1 was borderline
significant after the meta-analysis (OR¼1.06 (1.00–1.13)
P¼0.06). This association was nominal and mainly caused
by first-stage data. The ORs in all independent cohorts
are shown in Supplementary Table S2. Correction for age,
gender and BMI (when available) did not influence the
results.
Finally, we analyzed OGTT data for association of the
selected genes with differences in clinical variables like
glucose and insulin. Furthermore, association with BMI
was assessed when the data were available. No differences
were observed using different models (data not shown).
After completion of our study, a meta-analysis of three
T2DM GWAS appeared.40 The coverage of common varia-
tion in the 13 selected genes in the GWAS was between 80
and 100% except GTPBP3, which was covered for 50%. We
compared our results with the GWAS data, using the
OR-based analysis (Table 4). The G allele of rs2522138 in
SIRT4 was not associated with T2DM susceptibility in the
GWAS data (OR¼1.02 (0.93–1.11), P¼0.72). The C allele
of rs4917960 in PPRC1 showed an OR of 1.04 (0.97–1.12),
(P¼0.23) in the GWAS data, which is in the same direction
as observed in our study (OR¼1.06 (1.00–1.13), P¼0.06).
Two SNPs located in IARS2 (the C alleles of rs17007135 and
Table 3 Results of first and second-stage genotyping
MAF a First Stage Second Stage Meta-analysis
rs number Gene Controls Cases OR (95% CI) PAdd OR (95% CI) PAdd OR (95% CI) PAdd
rs1937b TFAM 0.14 0.09 0.66 (0.50–0.88) 0.005 1.00 (0.86–1.17) 0.97 0.91 (0.79–1.04) 0.17
rs4397793 TFAM 0.41 0.37 0.86 (0.72–1.03) 0.10 1.04 (0.97–1.11) 0.25 1.02 (0.95–1.08) 0.62
rs1049432 TFAM 0.19 0.14 0.77 (0.61–0.97) 0.03 1.00 (0.91–1.09) 0.95 0.97 (0.89–1.05) 0.39
rs4917960 PPRC1 0.38 0.42 1.12 (1.00–1.43) 0.05 1.05 (0.98–1.12) 0.21 1.06 (1.00–1.13) 0.06
rs17129583 GPAM 0.12 0.16 1.32 (1.02–1.70) 0.04 0.92 (0.84–1.02) 0.12 0.97 (0.88–1.06) 0.50
rs2792751 GPAM 0.26 0.24 0.87 (0.71–1.06) 0.18 1.01 (0.94–1.09) 0.81 0.99 (0.93–1.06) 0.82
rs535716 SIRT3 0.24 0.19 0.78 (0.63–0.96) 0.02 1.05 (0.97–1.13) 0.25 1.01 (0.94–1.09) 0.78
rs2522138c SIRT4 0.18 0.13 0.69 (0.54–0.88) 0.003 0.93 (0.85–1.02) 0.13 0.92 (0.85–1.00) 0.06
rs17085633 MTIF3 0.44 0.50 1.25 (1.05–1.50) 0.01 1.02 (0.97–1.09) 0.55 1.05 (0.98–1.11) 0.15
aMAF in first-stage genotyping (Hoorn study).
bSecond-stage genotyping only in NHS and Breda study (n¼3759).
cMeta-analysis includes Steno study.
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rs2289191) showed evidence of nominal association in the
GWAS meta-analysis (P¼6104 and P¼0.003, respec-
tively). Unfortunately, the assays for these two SNPs failed
in our study. None of the other SNPs in our 13 genes
showed evidence of association in the T2DM GWAS meta-
analysis.
Discussion
We analyzed 58 tagging SNPs in 13 genes involved in
mitochondrial function for association with T2DM sus-
ceptibility using a two-stage design. After meta-analysis of
the data of both stages, only rs2522138 in SIRT4 remained
borderline significant. However, after extension of the
second stage with samples from the Steno study, this
association did not remain significant.
For several gene variants measured in our study, there is
substantial heterogeneity of ORs between the first and
second stage, but not within each stage (Table 3 and
Supplementary Table S2). Heterogeneity between the
independent cohorts might be caused by the differences
in the age, gender or selection criteria used, and might
obscure true association (Supplementary Table S1). How-
ever, we were unable to identify the reasons for this
heterogeneity in our study. Differences in LD between the
measured and causal SNP are also an unlikely cause,
because the study participants in our cohorts are from
similar ancestry.41 In the context of testing multiple SNPs,
our nominal significant results in SIRT4 and PPRC1 should
be interpreted as consistent with statistical noise.
One of the limitations of our study is that it is
statistically underpowered to detect SNPs with a very small
impact or low allele frequency. Although power in the first
stage alone was low, we had at least a power of 80% at an
observed MAFX0.13 to detect ORs comparable to those
recently reported in GWAS (1.12–1.37) when first and
second stage are combined.40 Our negative results for these
13 genes are confirmed by the DIAGRAM GWAS meta-
analysis, which has a much higher power to detect also
more modest effects.38–40,42 Taken together, we can
exclude that common variants in the selected genes have
a major impact on T2DM susceptibility. Rare variants are
not covered by our approach; therefore, we cannot exclude
a role for such variants. Deep sequencing and analysis of
novel rare variants in large well-phenotyped cohorts
should provide more insight into these important issues.
Other nuclear-encoded mitochondrial genes are also not
among the top hits of reported T2DM GWAS.38–40,42,43
Nevertheless, earlier studies suggested that they may be
involved in T2DM susceptibility.3,44–47 Further combined
and detailed analysis of the available GWAS datasets, and
analysis of copy number and so-called low-frequency
intermediate-penetrance variants are necessary to fully
explore the role of nuclear-encoded mitochondrial genes
in the pathogenesis of T2DM.
In conclusion, we were unable to detect association of
common SNPs in 13 nuclear-encoded mitochondrial
candidate genes with T2DM or with related continuous
traits.
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